Patient-Reported Outcome Measures in Adult Patients Diagnosed with Epilepsy Being Treated with Perampanel

Brian D Moseley; Shaloo Gupta; Nate Way; Jonathon Wright; John C Rowland; Victoria E Barghout; Feride Frech; Craig Plauschinat

doi:10.2147/PROM.S343302

Patient-Reported Outcome Measures in Adult Patients Diagnosed with Epilepsy Being Treated with Perampanel

Patient Relat Outcome Meas. 2022 Feb 9:13:39-52. doi: 10.2147/PROM.S343302. eCollection 2022.

Authors

Brian D Moseley¹, Shaloo Gupta², Nate Way², Jonathon Wright², John C Rowland², Victoria E Barghout³, Feride Frech⁴, Craig Plauschinat⁴

Affiliations

¹ Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH, 45267, USA.
² Real World Evidence, Cerner Enviza, Malvern, PA, 19355, USA.
³ VEB HealthCare LLC, Morristown, NJ, 07960, USA.
⁴ Health Economics, Outcomes Research, and Real World Evidence, Eisai Inc., Nutley, NJ, 07110, USA.

Abstract

Background: Epilepsy is a complex disorder that can affect patients' medical, psychological, and social well-being. The purpose of this study was to evaluate the patient-reported outcome (PRO) measures of health-related quality of life (HRQoL), satisfaction, and adherence in adult patients diagnosed with epilepsy treated with perampanel in the United States (US).

Methods: A US-based, multicenter, observational cross-sectional survey was completed by 61 patients taking perampanel with or without other antiseizure medications (ASMs). Respondents were ≥18 years old, had a physician-confirmed diagnosis of epilepsy, used perampanel for ≥4 months, and provided informed consent. Patients responded to questions concerning their demographic characteristics, treatment history, experiences before perampanel, experiences while taking perampanel, HRQoL, treatment satisfaction, and medication adherence.

Results: Patients (N=61) were 42.8 years old on average; majority were female (63.9%) and white (75.4%). Mean time on perampanel was 2.5 years, with sodium channel blockers often (55.7%) used concomitantly with perampanel. Patients reported, on average, 5.5 (standard deviation [SD]=13.2) seizures/month after initiating perampanel, whereas these same patients reported experiencing 20.4 (SD=60.0) seizures/month prior to perampanel. When comparing their experience on perampanel with their experience with previous ASMs, more patients "strongly agreed" that perampanel allowed them to live a more normal life (36.1% vs 27.5%) and worked as intended if they missed taking a dose (16.4% vs 7.8%). Average satisfaction scores were high, with ratings of 71.8 for effectiveness, 84.0 for convenience, and 71.9 for global satisfaction (0-100 scores). Perampanel use was associated with improvements in HRQoL and fewer symptoms of depression and anxiety. The majority of patients were adherent (62.3%) to perampanel.

Discussion: Perampanel use was associated with reductions in number of seizures, better HRQoL, and high adherence rates. These results provide initial evidence that perampanel can be an effective, tolerable, and valid option for patients with epilepsy in the real world.

Keywords: epilepsy; healthcare resource use; medication adherence; perampanel; quality of life.

Grants and funding

The authors would like to acknowledge the financial support from Eisai Inc. The funders had no role in data collection, analysis, and interpretation of results.